Amica Mutual Insurance Co. Buys 15,087 Shares of Abbott Laboratories (NYSE:ABT)

Amica Mutual Insurance Co. boosted its position in shares of Abbott Laboratories (NYSE:ABT - Free Report) by 14.7% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 117,532 shares of the healthcare product maker's stock after acquiring an additional 15,087 shares during the period. Abbott Laboratories makes up approximately 1.4% of Amica Mutual Insurance Co.'s holdings, making the stock its 14th largest holding. Amica Mutual Insurance Co.'s holdings in Abbott Laboratories were worth $12,937,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. International Assets Investment Management LLC lifted its holdings in shares of Abbott Laboratories by 14,037.9% during the 4th quarter. International Assets Investment Management LLC now owns 1,349,176 shares of the healthcare product maker's stock worth $148,504,000 after acquiring an additional 1,339,633 shares during the period. Wellington Management Group LLP lifted its stake in Abbott Laboratories by 4.3% during the third quarter. Wellington Management Group LLP now owns 31,208,711 shares of the healthcare product maker's stock worth $3,022,564,000 after purchasing an additional 1,298,219 shares during the period. Envestnet Asset Management Inc. boosted its holdings in Abbott Laboratories by 30.8% during the third quarter. Envestnet Asset Management Inc. now owns 3,627,373 shares of the healthcare product maker's stock valued at $351,311,000 after purchasing an additional 853,997 shares in the last quarter. Grantham Mayo Van Otterloo & Co. LLC grew its stake in shares of Abbott Laboratories by 28.0% in the 3rd quarter. Grantham Mayo Van Otterloo & Co. LLC now owns 3,664,856 shares of the healthcare product maker's stock valued at $354,941,000 after purchasing an additional 801,191 shares during the period. Finally, Canada Pension Plan Investment Board raised its holdings in shares of Abbott Laboratories by 47.7% in the 3rd quarter. Canada Pension Plan Investment Board now owns 2,423,715 shares of the healthcare product maker's stock worth $234,737,000 after buying an additional 783,090 shares in the last quarter. Institutional investors and hedge funds own 75.18% of the company's stock.

Abbott Laboratories Trading Down 0.2 %

ABT traded down $0.24 during mid-day trading on Monday, reaching $107.29. The stock had a trading volume of 3,306,015 shares, compared to its average volume of 5,632,260. The stock has a market capitalization of $186.17 billion, a P/E ratio of 33.42, a P/E/G ratio of 2.59 and a beta of 0.74. Abbott Laboratories has a 52 week low of $89.67 and a 52 week high of $121.64. The company has a debt-to-equity ratio of 0.35, a quick ratio of 1.16 and a current ratio of 1.64. The firm's fifty day simple moving average is $113.50 and its two-hundred day simple moving average is $108.34.

Abbott Laboratories (NYSE:ABT - Get Free Report) last issued its quarterly earnings results on Wednesday, April 17th. The healthcare product maker reported $0.98 EPS for the quarter, topping the consensus estimate of $0.96 by $0.02. Abbott Laboratories had a net margin of 13.96% and a return on equity of 20.32%. The company had revenue of $9.96 billion during the quarter, compared to analysts' expectations of $9.88 billion. During the same quarter in the previous year, the company earned $1.03 EPS. Abbott Laboratories's revenue was up 2.2% on a year-over-year basis. On average, equities analysts predict that Abbott Laboratories will post 4.62 EPS for the current year.

Abbott Laboratories Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, May 15th. Shareholders of record on Monday, April 15th will be issued a dividend of $0.55 per share. This represents a $2.20 dividend on an annualized basis and a yield of 2.05%. The ex-dividend date is Friday, April 12th. Abbott Laboratories's dividend payout ratio (DPR) is currently 68.54%.

Insider Transactions at Abbott Laboratories

In related news, EVP Andrea F. Wainer sold 12,500 shares of Abbott Laboratories stock in a transaction that occurred on Friday, February 23rd. The shares were sold at an average price of $120.00, for a total transaction of $1,500,000.00. Following the transaction, the executive vice president now owns 78,704 shares of the company's stock, valued at approximately $9,444,480. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, EVP Daniel Gesua Sive Salvadori sold 963 shares of the business's stock in a transaction that occurred on Friday, March 1st. The stock was sold at an average price of $118.50, for a total value of $114,115.50. Following the completion of the transaction, the executive vice president now directly owns 125,697 shares in the company, valued at approximately $14,895,094.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Andrea F. Wainer sold 12,500 shares of the firm's stock in a transaction that occurred on Friday, February 23rd. The stock was sold at an average price of $120.00, for a total transaction of $1,500,000.00. Following the sale, the executive vice president now owns 78,704 shares in the company, valued at $9,444,480. The disclosure for this sale can be found here. In the last ninety days, insiders sold 13,935 shares of company stock worth $1,670,048. 0.47% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

ABT has been the topic of a number of analyst reports. Royal Bank of Canada lowered their price target on Abbott Laboratories from $128.00 to $125.00 and set an "outperform" rating on the stock in a research report on Thursday, April 18th. Raymond James reiterated a "buy" rating and set a $124.00 target price on shares of Abbott Laboratories in a research report on Wednesday, April 24th. Evercore ISI boosted their price target on shares of Abbott Laboratories from $120.00 to $125.00 and gave the company an "outperform" rating in a research report on Thursday, April 4th. Citigroup upped their price objective on shares of Abbott Laboratories from $126.00 to $128.00 and gave the stock a "buy" rating in a research note on Wednesday, April 3rd. Finally, Barclays cut their target price on shares of Abbott Laboratories from $141.00 to $140.00 and set an "overweight" rating for the company in a research note on Monday, April 22nd. Three investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $121.50.

About Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.

Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.